Jeremy Duffield, M.D., Ph.D., FRCP, is a distinguished medical professional and researcher who currently serves as the Chief Scientific Officer at PRIME Medicine Inc. Dr. Duffield's academic journey is marked by his dual degrees in medicine and philosophy, which he obtained from the University of Cambridge. He further honed his expertise by completing his residency and fellowship training at prestigious institutions such as the University of California, San Francisco, and Harvard Medical School. His commitment to advancing medical knowledge is evident through his fellowship in the Royal College of Physicians, a testament to his outstanding contributions to the field. Throughout his career, Dr. Duffield has made significant strides in the realm of regenerative medicine and kidney disease research. He has authored numerous peer-reviewed articles and has been a principal investigator on several groundbreaking studies that have advanced our understanding of renal fibrosis and repair mechanisms. His work has not only contributed to the scientific community but has also paved the way for novel therapeutic approaches. Dr. Duffield's achievements have been recognized with several awards, including the prestigious American Society of Nephrology Young Investigator Award, which underscores his impact on nephrology and beyond. As the Chief Scientific Officer at PRIME Medicine Inc., Dr. Duffield plays a pivotal role in steering the company's research and development efforts. His leadership is instrumental in driving the company's mission to develop innovative gene editing technologies that address unmet medical needs. Under his guidance, PRIME Medicine Inc. continues to explore new frontiers in precision medicine, aiming to bring transformative treatments to patients worldwide. Dr. Duffield's vision and expertise are crucial in positioning the company at the forefront of medical innovation.